Xiadafil VIP Tabs Recall

On Tuesday, the FDA issued an alert warning consumers not to buy or use Xiadafil VIP Tablets, which are sold as a dietary supplement over the internet for sexual enhancement and to treat erectile dysfunction. The FDA has requested that the manufacturer, SEI Pharmaceuticals, issue a Xiadafil VIP Tabs recall because the tablets contain an undeclared ingredient which could impact the users blood pressure and lead to potentially life-threatening injuries.

Although Xiadafil VIP Tabs are marketed as an “all-natural” product, an FDA chemical analysis found that the tablets contain hydroxyhomosildenafil, which an analog of the active pharmaceutical ingredient in the prescription drug Viagra. The FDA has called Xiadafil VIP an “illegally marketed drug” due to the undeclared ingredient.

“Because these products are labeled as ‘all natural dietary supplements,’ consumers may assume that they are harmless and pose no health risk,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research.

The undeclared ingredient could interact with nitrates found in several prescription medications taken by those with diabetes, high blood pressure, high cholesterol or heart disease. As a side effects of Xiadafil VIP Tabs, users could suffer extremely low blood pressure or other life-threatening problems.

The Xadafil VIP Tab recall applies to bottles containing 8 tablets (lot number 6K029) and blister cards containing two tablets (lot number 6K029-SEI), which carry an expiration date of September 2009 (09/09).